Skip to content
OpenCapital
Get started

AbbVie ABBV Skyrizi — Net revenues

Other product segments

Rinvoq
$2.12B+23.3%
All other
$1.03B-18.2%
Botox Therapeutic
$1.01B+16.5%
Vraylar
$905M+18.3%
Venclexta
$770M+15.8%
Humira
$688M-38.6%
Botox Cosmetic
$668M+20.1%
Imbruvica
$556M-24.7%
Mavyret
$351M+14.7%
Ubrelvy
$339M+41.3%
Qulipta
$296M+53.4%
Other Aesthetics
$286M-9.2%
Linzess
$283M+91.2%
Juvederm Collection
$232M+0.4%
Vyalev
$201M+219%
Elahere
$198M+10.6%
Other Neuroscience
$125M-19.4%
Epkinly
$83M+62.7%

Similar metrics at other companies

Biogen logo
BIIBSKYCLARYS — Total Revenue
$167.9M+28.9%
Ligand Pharmaceuticals logo
LGNDRylaze — Total revenues and income
$3.22M+3.3%
ESP
ESPRProduct sales, net — Total Revenues
$43.4M+24.3%
Arcutis Biotherapeutics, Inc. logo
ARQTZORYVE foam — Product revenue, net
$49.63M+64.1%
Vertex Pharmaceuticals logo
VRTXProduct revenues, net — Product revenues, net
$2.99B+8.2%
Ardelyx logo
ARDXProduct sales, net — Total revenues
$93.37M+37.7%

Other financials

Income statement

See full
Revenue$15.0B+12.4%
Gross profit$10.8B+15.4%
Operating income$4.0B+6.9%
Net income$695.0M-46.0%
EPS (diluted)$0.39-45.8%

Balance sheet

See full
Cash & equivalents$9.4B+81.5%
Total debt$62.4B+1.8%
Total equity-$6.7B-569%
Total assets$136.46B+0.2%

Cash flow

See full
Operating cash flow$3.8B+134%
CapEx$265.0M+12.8%
Free cash flow$3.6B+155%

Valuation

See full
Market cap$465.2B+39.1%
P/E128×+39.1×
P/S7.4×+1.7×

Profitability

See full
Gross margin70.7%0.0pp
Operating margin24.4%—
Net margin5.8%-1.5pp
FCF margin31.8%+5.0pp

Returns & leverage

See full
Return on equity89%+32.7pp
Debt / equity46.6×+38.6×
Current ratio0.8×0.0×

Where this comes from

Reported directly by AbbVie in its filing.

Tagged under the XBRL concept us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax.

The official record: AbbVie’s 10-Q, filed May 8, 2026, on SEC EDGAR. View the filing →

Ask your AI about AbbVie's skyrizi — net revenues.

Connect your AI assistant and compare segments, right in your chat.

Connect your AI
Harbor at dusk
Claude

Questions, answered.

What is AbbVie's skyrizi — net revenues?
AbbVie (ABBV) reported skyrizi — net revenues of $4.48B in Q1 2026.
How has AbbVie's skyrizi — net revenues changed year-over-year?
AbbVie's skyrizi — net revenues increased by 30.9% year-over-year, from $3.43B to $4.48B.
What is the long-term trend for AbbVie's skyrizi — net revenues?
Over 4 years (2021 to 2025), AbbVie's skyrizi — net revenues has grown at a 56.3% compound annual growth rate (CAGR), from $2.94B to $17.56B.
What does skyrizi — net revenues mean?
This metric represents the total gross sales of the specific pharmaceutical product line after accounting for returns, allowances, and rebates. It serves as a primary indicator of the product's market adoption, competitive positioning in the immunology therapeutic area, and its contribution to the company's overall top-line growth. Monitoring this revenue stream is essential for assessing the commercial success of the drug's lifecycle and its role in offsetting revenue declines from legacy products.